-
'First of its kind' study shows adult immunization programs can deliver up to 19 times the return on initial investment when all benefits are measured
-
The findings highlight an opportunity to reduce pressure on health systems by adopting a prevention-first approach, including adult immunization programmes.
-
The report, released ahead of World Immunization Week, reveals wide variation across countries in the availability of evidence to evaluate adult vaccination.
London, April 17, 2024–(BUSINESS WIRE)–A new report published today reveals that adult vaccination programs can return up to 19 times their initial investment when the full range of economic and social benefits are assessed. The 19x return equates to a net financial benefit to society of up to US$4,637 per complete individual vaccination course.
This study is a first-of-its-kind analysis of the adult immunization program conducted by the Office for Health and Economic Affairs (OHE) on behalf of IFPMA (1), and examines the availability of vaccines to determine the broader economic situation. We looked at four available adult vaccines across 10 countries. and social impact.
This study focuses on vaccines that prevent influenza (influenza), pneumococcal disease, respiratory syncytial virus (RSV), and herpes zoster (herpes zoster), and focuses on vaccine programs in countries representing different health systems, demographics, and demographics. We are investigating the availability of . Vaccine schedule – Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, United States.
The report concludes that vaccination programs provide significant returns on government investment through cost savings within the health system and wider socio-economic benefits. Preventing disease reduces visits to doctors and hospitals, frees up valuable resources elsewhere, ensures a healthy and active workforce throughout life, and increases economic productivity. I can.
This data also indicates that adult immunization can provide proportional socio-economic benefits to pediatric immunization programs (2). Nevertheless, access to vaccination for adults is inconsistent around the world and its inclusion in routine immunization schedules is limited.
Professor Lotte Steuten, Deputy Chief Executive Officer of OHE and co-author of the report, said:
“Increasing pressures on sick health systems, including an aging population, make it imperative to move towards a prevention-first mindset. “We make a convincing case that it plays a critical role in the transition.”
”Our findings show that when governments invest in adult immunization programs, the costs are offset many times by the benefits to society. These benefits will be realized through benefits to individuals, families and communities, and provide a clear call to action for countries that have not yet implemented or scaled up robust vaccination schedules. ”
Researchers used an established vaccine value framework to gather evidence, but found that data across many components was lacking. This finding, coupled with the lack of an agreed method to capture some factors, suggests that the positive benefits shown may underestimate the full value that adult vaccines bring to society. means high.
The report is being released ahead of WHO's World Immunization Week, and addressing these evidence gaps is critical to achieving the goals of the Immunization Agenda 2030. This includes “Everyone benefits from recommended vaccinations throughout life” explicitly explains the need for data-driven implementation.
IFPMA Vaccine Policy Director Leticia Biggar added:
“This important study broadens the horizon to demonstrate that adult vaccination programs are delivering real benefits to health systems and societies around the world.
”Vaccines are one of the most effective public health measures and can also be a powerful driver of more productive economies and resilient societies.
“A better understanding of these benefits is important to ensure that those who benefit from the adult immunization program have access to it.”
Maarten Postma, professor of pharmacoeconomics at the University of Groningen in the Netherlands and reviewer of the report's methodology, commented:
“Assessing the value of adult immunization will give policy makers a clearer picture of the associated benefits and costs. We adopted a rigorous methodological framework to investigate and assess its value.”
(1) The International Federation of the Pharmaceutical Manufacturers (IFPMA) represents the innovative pharmaceutical industry in official relations with the United Nations.
(2) Using the statistical value of life approach, the return on investment for 10 childhood immunization programs was 51.0 from 2011 to 2020 and 52.2 from 2021 to 2030 (Source: https:/ /www.healthaffairs.org/doi/10.1377/)hlthaff.2020.00103).
-end-
Note to editor
About the report
The full report, The Socioeconomic Value of Adult Immunization Programs, is available at https://www.ohe.org/publications/the-socio-economic-value-of-Adult-immunization-programmes/.
About Oe
With more than 60 years of expertise, the Office of Health Economics (OHE) is the world's oldest independent health economics research organization. Every day, we work to improve health care through pioneering and innovative research, analysis and education.
As a global thought leader and publisher in the economics of health, healthcare, and life sciences, we partner with universities, governments, health systems, and the pharmaceutical industry to research and respond to global health challenges. doing.
As a government-recognized independent research institute and not-for-profit organization, our international reputation for research quality and independence is at the forefront of everything we do. OHE provides pioneering independent resources, research, and analysis in health economics, health policy, and health statistics. Our work informs decision-making on health and pharmaceutical issues at the global level.
All of our work is available for free online at www.ohe.org.
About IFPMA
The International Federation of Pharmaceutical Manufacturers (IFPMA) represents more than 90 innovative pharmaceutical companies and organizations from around the world. Our industry's approximately 3 million employees discover, develop and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has an official relationship with the United Nations and provides industry expertise to help the global health community improve the lives of people everywhere. For more information, please visit ifpma.org.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240417519822/en/
contact address
For more information, including high-resolution photos, or to arrange an information session or interview, please contact us below.
Tim Watson
Director of Marketing & Communications,
Health Economics Bureau
Phone: +44 (0)7866 288456
E: twatson@ohe.org
